Navigation Links
United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
Date:3/21/2011

SILVER SPRING, Md., March 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

FREEDOM-C(2) is a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulation of treprostinil diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients receiving an endothelin receptor antagonist and/or a phosphodiesterase-5 inhibitor.

The FREEDOM-C(2) study randomized 313 patients, compared to a target enrollment of 300 patients.  The primary endpoint of the trial is change in six-minute walk distance at Week 16 in the treatment group compared to placebo.

"Completion of enrollment in FREEDOM-C(2) represents another significant milestone toward the planned filing of the UT-15C NDA," said Roger Jeffs, Ph.D., President and Chief Operating Officer of United Therapeutics. "This study, if successful, will support the use of UT-15C as add-on therapy to currently approved oral medications, and should significantly enhance early adoption and market uptake of UT-15C."

United Therapeutics expects to unblind and announce preliminary analysis of the FREEDOM-C(2) study results in September 2011.

About United Therapeutics Corporation

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations on the timing of unblinding of the FREEDOM-C(2) study, our belief that the FREEDOM-C(2) study unblinding will bring us closer to the goal of achieving an approved oral prostacyclin therapy for PAH and our expectations that the study will enhance early adoption and market uptake of UT-15C.  These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 21, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
2. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
3. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
4. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
5. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
6. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
7. Report Details How States Respond to Citizens United Decision
8. United Nations' World Population Day Calls Attention to Key Global Issues
9. United Therapeutics and Lees Pharmaceutical Sign Remodulin Distribution Agreement for China
10. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
11. Abt Bio-Pharma Solutions, Inc. Acquired by United BioSource Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
Breaking Biology News(10 mins):